Addressing the challenge of platinum-resistant ovarian cancer: the role of mirvetuximab soravtansine

被引：0
|
作者：
Shaukat, Ayesha [1 ]
Shakeel, Laiba [1 ]
Khan, Afsheen [1 ]
Irfan, Hamza [2 ]
Akilimali, Aymar [3 ]
机构：
[1] Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan
[2] Shaikh Khalifa Bin Zayed Al Nahyan Med & Dent Coll, Dept Internal Med, Lahore, Pakistan
[3] Med Res Circle, Dept Res, Goma, DEM REP CONGO
来源：
ANNALS OF MEDICINE AND SURGERY | 2025年 / 87卷 / 01期
关键词：
EXPRESSION; CISPLATIN; WOMEN;
D O I：
10.1097/MS9.0000000000002759
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [41] Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
    Huang, Shuai
    Sheng, Guihua
    Lv, Qiubo
    Li, Ye
    Meng, Qingwei
    Gao, Xuexiao
    Shang, Zhiyuan
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
  • [42] Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer
    Schumann, Canan
    Chan, Stephanie
    Khalimonchuk, Oleh
    Khal, Shannon
    Moskal, Vitaliya
    Shah, Vidhi
    Alani, Adam W. G.
    Taratula, Olena
    Taratula, Oleh
    MOLECULAR PHARMACEUTICS, 2016, 13 (06) : 2070 - 2083
  • [43] Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study
    Tatsuki, Shunsuke
    Shoji, Tadahiro
    Abe, Marina
    Tomabechi, Hidetoshi
    Takatori, Eriko
    Kaido, Yoshitaka
    Nagasawa, Takayuki
    Kagabu, Masahiro
    Aida, Takeshi
    Baba, Tsukasa
    ANTICANCER RESEARCH, 2022, 42 (09) : 4603 - 4610
  • [44] Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports
    Soeda, Shu
    Watanabe, Takafumi
    Kamo, Norihito
    Sato, Tetsu
    Okabe, Chikako
    Ueda, Makiko
    Endo, Yuta
    Manabu, Kojima
    Nomura, Shinji
    Furukawa, Shigenori
    Nishigori, Hidekazu
    Takahashi, Toshifumi
    Fujimori, Keiya
    ANTICANCER RESEARCH, 2020, 40 (09) : 5263 - 5270
  • [45] Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
    Wu, Yawen
    Zhang, Xiaoyan
    Li, Lian
    Yang, Wen
    Yan, Zhifeng
    Gu, Chenglei
    Zhang, Zhe
    Zhou, Jiahuan
    Liu, Lulu
    Ye, Mingxia
    Meng, Yuanguang
    ONCOTARGETS AND THERAPY, 2022, 15 : 973 - 979
  • [46] Tobacco Mosaic Virus-Delivered Cisplatin Restores Efficacy in Platinum-Resistant Ovarian Cancer Cells
    Franke, Christina E.
    Czapar, Anna E.
    Patel, Ravi B.
    Steinmetz, Nicole F.
    MOLECULAR PHARMACEUTICS, 2018, 15 (08) : 2922 - 2931
  • [47] Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
    Singh, Tanya
    Neal, Adam
    Dibernardo, Gabriella
    Raheseparian, Neela
    Moatamed, Neda A.
    Memarzadeh, Sanaz
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 60 (03) : 1 - 11
  • [48] Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen
    Tu, Ya-Ping
    Lagraauw, H. Maxime
    Method, Michael
    Wang, Yuemei
    Hanze, Eva
    Li, Lingling
    Parrott, Timothy
    Sloss, Callum M.
    Westin, Eric H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 91 (01) : 220 - 231
  • [49] The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients
    Safra, Tamar
    Asna, Noam
    Veizman, Anat
    Shpigel, Shulem
    Matcejevsky, Dianna
    Inbar, Moshe
    Grisaru, Dan
    ANTI-CANCER DRUGS, 2014, 25 (03) : 340 - 345
  • [50] Short-Term Serum Deprivation Confers Sensitivity to Taxanes in Platinum-Resistant Human Ovarian Cancer Cells
    Isonishi, Seiji
    Saito, Motoaki
    Saito, Misato
    Tanaka, Tadao
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (09) : 1547 - 1554
12345